| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/19/2012 | CA2805572A1 Modified single domain antigen binding molecules and uses thereof |
| 01/19/2012 | CA2805414A1 Anti-addl monoclonal antibody and uses thereof |
| 01/19/2012 | CA2805388A1 Stabilized formulations containing anti-ngf antibodies |
| 01/19/2012 | CA2805327A1 Method for producing toxoids using alpha - dicarbonyl compounds |
| 01/19/2012 | CA2805300A1 Human papillomavirus e7 antigen compositions and uses thereof |
| 01/19/2012 | CA2805091A1 Pharmaceutical compositions and methods of treatment |
| 01/19/2012 | CA2804969A1 A combination pharmaceutical composition and methods of treating diseases or conditions associated with the cardiovascular system |
| 01/19/2012 | CA2804964A1 Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract |
| 01/19/2012 | CA2804278A1 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of aspartyl-trna synthetases |
| 01/19/2012 | CA2804191A1 Prevention and treatment of pain using monoclonal antibodies and antibody fragments to lysophosphatidic acid |
| 01/19/2012 | CA2804121A1 Modified viral strains, and method for improving the production of vaccine seeds of the influenza virus |
| 01/19/2012 | CA2803675A1 Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer |
| 01/19/2012 | CA2802283A1 Live attenuated parvovirus |
| 01/19/2012 | CA2799036A1 Superior efficacy of cd37 antibodies in cll blood samples |
| 01/18/2012 | EP2407542A1 Recombinant vaccines against caligid copepods (sea lice) and antigen sequences thereof |
| 01/18/2012 | EP2407537A1 Humanized pcrv antibody having anti-pseudomonal activity |
| 01/18/2012 | EP2407486A1 Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8-associated disorders |
| 01/18/2012 | EP2407480A1 Materials and methods for respiratory disease control in canines |
| 01/18/2012 | EP2407178A2 Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease |
| 01/18/2012 | EP2407177A1 Adenovirus vaccine vectors |
| 01/18/2012 | EP2407173A1 Method and compositions to induce apoptosis of tumoral cells expressing SHH |
| 01/18/2012 | EP2407161A1 An antitumoral combination comprising ombrabulin and bevacizumab |
| 01/18/2012 | EP2406627A2 A pkn3/rhoc macromolecular complex and methods of use therefor |
| 01/18/2012 | EP2406395A1 Diagnosis and treatment of cell proliferation and differentiation disorders based on the fmn2 gene |
| 01/18/2012 | EP2406290A2 Antigen presenting cell targeted cancer vaccines |
| 01/18/2012 | EP2406289A2 Antigen presenting cell targeted anti-viral vaccines |
| 01/18/2012 | EP2406288A2 Antigen presenting cell targeted vaccines |
| 01/18/2012 | EP2406286A2 Anti-cd40 antibodies and uses thereof |
| 01/18/2012 | EP2406285A1 Generation, expression and characterization of the humanized k33n monoclonal antibody |
| 01/18/2012 | EP2406284A2 Anti-bcma antibodies |
| 01/18/2012 | EP2406283A1 Antibody molecules having binding specificity for human il-13 |
| 01/18/2012 | EP2406277A1 New strain of salmonella enterica s. typhimurium, its use and a method to obtain a therapeutic vaccine vector |
| 01/18/2012 | EP2405945A2 Non-integrating retroviral vector vaccines |
| 01/18/2012 | EP2405940A1 Antibodies to clostridium difficile toxins |
| 01/18/2012 | EP2405939A1 Optimized early-late promoter combined with repeated vaccination favors cytotoxic t cell response against antigens in replication deficient recombinant virus vaccines |
| 01/18/2012 | EP2405938A2 Nontypable haemophilus influenzae antigens |
| 01/18/2012 | EP2405937A1 Treatment of a cancer using a combination of bendamustine and an anti-cd20 antibody |
| 01/18/2012 | EP2405929A1 Treatment methods for autoimmune disorders |
| 01/18/2012 | EP2327413A9 Pharmaceutical composition comprising FGF18 and IL-1 antagonist and method of use |
| 01/18/2012 | EP2262839B1 Use of an anti-cd151 antibody for early treatment of cancer |
| 01/18/2012 | EP1957102B1 Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors |
| 01/18/2012 | EP1883701B1 Expression of viral proteins in plants |
| 01/18/2012 | EP1810690B1 Anti-IL-5 receptor antibody for use in treating endometriosis. |
| 01/18/2012 | EP1808446B1 Il-18 receptor antagonist and pharmaceutical composition containing the antagonist |
| 01/18/2012 | EP1553975B1 Optimized fc variants and methods for their generation |
| 01/18/2012 | EP1257822B1 Her-2 binding antagonists |
| 01/18/2012 | EP1053256B9 Antibodies to death receptor 4 (dr4) and uses thereof |
| 01/18/2012 | CN1951962B Polypeptide for preparing antineoplastic antibody and its uses |
| 01/18/2012 | CN102326083A Method for inhibiting neurodegeneration |
| 01/18/2012 | CN102326075A Cellulose gel for purification of immunoglobulin |
| 01/18/2012 | CN102325885A Methods and compositions for diagnosis and treatment of cancer |
| 01/18/2012 | CN102325884A Hypo-immunogenic streptavidin and use thereof |
| 01/18/2012 | CN102325875A Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
| 01/18/2012 | CN102325796A Anti-human [alpha]9 integrin antibody and use thereof |
| 01/18/2012 | CN102325795A Antibodies against tissue factor pathway inhibitor |
| 01/18/2012 | CN102325793A Myostatin binding proteins |
| 01/18/2012 | CN102325550A Combination of photodynamic therapy and anti-VEGF agents in the treatment of unwanted choroidal neovasculature |
| 01/18/2012 | CN102325549A Treatment of cancer with umanized anti-egfr igg1 antibody and irinotecan |
| 01/18/2012 | CN102325548A Methods and compositions for diagnosis and treatment of cancer |
| 01/18/2012 | CN102325547A Anticancer composition comprising antitumor agent and substance having inhibitory effects on L1CAM activity and expression |
| 01/18/2012 | CN102325546A Compositions and methods for induction of antigen-specific tolerance |
| 01/18/2012 | CN102321653A Applications of man-mouse chimeric CD4 (cluster of differentiation 4) plasmid and multiclonal antibody in inhibiting HIV (human immunodeficiency virus) infection |
| 01/18/2012 | CN102321639A Preparation method of virus-like particles (VLPs) of Chikungunya virus (CHIKV) and its application |
| 01/18/2012 | CN102321638A New porcine reproductive and respiratory syndrome virus ORF5 modified gene and application thereof |
| 01/18/2012 | CN102321636A Protein for gene recombinant prokaryotic expression of duck plague virus gG as well as preparation method and application thereof |
| 01/18/2012 | CN102321635A Preparation method for human papillomaviral empty capsid particles, and products thereof |
| 01/18/2012 | CN102321634A Preparation method of mink enteritis parvovirus empty capsid antigen particles |
| 01/18/2012 | CN102321626A Means for inhibiting the expression of protein kinase 3 |
| 01/18/2012 | CN102321591A Assembly mechanism of virus-like particle of hepatitis E virus and preparation method thereof |
| 01/18/2012 | CN102321547A Recombination yeast engineering bacteria expressing reticuloendotheliosis virus (REV) Gp90 protein, its construction method and application |
| 01/18/2012 | CN102321180A Polypeptide fragment composition and application in preparation of porcine reproductive and respiratory syndrome vaccine thereof |
| 01/18/2012 | CN102321173A Humanized macrophage inhibitory factor 1 monoclonal antibody and application thereof |
| 01/18/2012 | CN102319441A Preparation method of PLGA swine influenza DNA vaccine microsphere |
| 01/18/2012 | CN102319440A Preparation method of porcine parvovirus genetic engineering vaccine |
| 01/18/2012 | CN102319431A Monoclonal antibody for detecting and treating senile dementia |
| 01/18/2012 | CN102319430A Antibody formulations in histidine-acetate buffer |
| 01/18/2012 | CN102319429A Peptide-based passive immunization therapy for treatment of atherosclerosis |
| 01/18/2012 | CN102319428A Glycosylceramide adjuvant for saccharide antigens |
| 01/18/2012 | CN102319427A Injectable vaccines against multiple meningococcal serogroups |
| 01/18/2012 | CN102319426A Preparation method of specific tumor vaccine for removing regulatory T cells |
| 01/18/2012 | CN102319417A Moderating the effect of endotoxins |
| 01/18/2012 | CN101405024B Drug-polymer conjugates |
| 01/18/2012 | CN101223448B Pretreatment of a biological sample from an autoimmune disease subject |
| 01/18/2012 | CN101087803B Pasteurella multocida vaccine |
| 01/18/2012 | CN101014364B Anti-ngf antibodies and methods using same |
| 01/17/2012 | US8097697 Tumor antigen protein SART-3 and tumor antigen peptides thereof |
| 01/17/2012 | US8097598 Porcine CTLA-4 for xenograft-specific immunosuppression |
| 01/17/2012 | US8097593 Lipid A and other carbohydrate ligand analogs |
| 01/17/2012 | US8097459 Methods and compositions for increasing replication capacity of an influenza virus |
| 01/17/2012 | US8097453 Recombinant viral-based malaria vaccines |
| 01/17/2012 | US8097430 Antigen targeting |
| 01/17/2012 | US8097261 Roundworm coproantigen detection |
| 01/17/2012 | US8097260 Lipid a deficient mutants of Neisseria meningitidis |
| 01/17/2012 | US8097257 MAGE3 polypeptides |
| 01/17/2012 | US8097256 Cancer vaccines and vaccination methods |
| 01/17/2012 | US8097255 Mammalian receptor protein DCRS5; methods of treatment |
| 01/17/2012 | US8097254 Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| 01/17/2012 | US8097253 Methods for inhibiting angiogenesis |
| 01/17/2012 | US8097252 Methods and compositions for administering therapeutic and diagnostic agents |
| 01/17/2012 | US8097251 Functional heavy chain antibodies, fragments thereof, library thereof and methods of production thereof |